TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION for Hypotension

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
UAB Hospital-Highlands, Birmingham, AL
Hypotension+2 More
TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This prospective study will analyze the need for deliberate hypotensive anesthesia (DHA) during orthognathic surgery when tranexamic acid (TXA) is administered. DHA has been proven to be effective although it comes with multiple risks related to organ hypoperfusion including kidney injury, stroke, and cardiac ischemia. Therefore, it may be potentially safer for patients to avoid deliberate hypotensive anesthesia if TXA alone adequately controls blood loss and provides adequate surgical site visualization.

Eligible Conditions

  • Hypotension
  • Blood Loss, Surgical

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Hypotension

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Estimated Blood Loss
Mean Arterial Pressure
Surgeon's Analysis of Surgical Field Visualization

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Hypotension

Trial Design

1 Treatment Group

Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION · No Placebo Group · Phase 4

Patients Receiving Tranexamic Acid with Avoidance of Hypotensive AnesthesiaExperimental Group · 2 Interventions: Avoidance of Deliberate Hypotensive Anesthesia, TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION · Intervention Types: Other, Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Closest Location: UAB Hospital-Highlands · Birmingham, AL
Photo of Birmingham 1Photo of Birmingham 2Photo of Birmingham 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Hypotension
0 CompletedClinical Trials

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,400 Previous Clinical Trials
2,210,936 Total Patients Enrolled
1 Trials studying Hypotension
12 Patients Enrolled for Hypotension
Brian Kinard, DMD, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.